DE69326772D1 - Verfahren zur steigerung der arzneistoffabgabe mit modifizierten saponinen - Google Patents

Verfahren zur steigerung der arzneistoffabgabe mit modifizierten saponinen

Info

Publication number
DE69326772D1
DE69326772D1 DE69326772T DE69326772T DE69326772D1 DE 69326772 D1 DE69326772 D1 DE 69326772D1 DE 69326772 T DE69326772 T DE 69326772T DE 69326772 T DE69326772 T DE 69326772T DE 69326772 D1 DE69326772 D1 DE 69326772D1
Authority
DE
Germany
Prior art keywords
saponines
modified
drug delivery
increasing drug
increasing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69326772T
Other languages
English (en)
Other versions
DE69326772T2 (de
Inventor
Charlotte A Kensil
Sean Soltysik
Dante J Marciani
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aquila Biopharmaceuticals Inc
Original Assignee
Cambridge Biotech Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cambridge Biotech Corp filed Critical Cambridge Biotech Corp
Publication of DE69326772D1 publication Critical patent/DE69326772D1/de
Application granted granted Critical
Publication of DE69326772T2 publication Critical patent/DE69326772T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
DE69326772T 1992-07-02 1993-07-01 Verfahren zur steigerung der arzneistoffabgabe mit modifizierten saponinen Expired - Fee Related DE69326772T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/906,870 US5273965A (en) 1992-07-02 1992-07-02 Methods for enhancing drug delivery with modified saponins
PCT/US1993/006348 WO1994001118A1 (en) 1992-07-02 1993-07-01 Methods for enhancing drug delivery with modified saponins

Publications (2)

Publication Number Publication Date
DE69326772D1 true DE69326772D1 (de) 1999-11-18
DE69326772T2 DE69326772T2 (de) 2000-06-29

Family

ID=25423119

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69326772T Expired - Fee Related DE69326772T2 (de) 1992-07-02 1993-07-01 Verfahren zur steigerung der arzneistoffabgabe mit modifizierten saponinen

Country Status (11)

Country Link
US (2) US5273965A (de)
EP (1) EP0658111B1 (de)
JP (1) JP3684370B2 (de)
AU (1) AU687005B2 (de)
BR (1) BR9306594A (de)
CA (1) CA2139437A1 (de)
DE (1) DE69326772T2 (de)
FI (1) FI946173A (de)
HU (1) HUT73814A (de)
MX (1) MX9303977A (de)
WO (1) WO1994001118A1 (de)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5583112A (en) * 1987-05-29 1996-12-10 Cambridge Biotech Corporation Saponin-antigen conjugates and the use thereof
NL9002314A (nl) * 1990-10-23 1992-05-18 Nederlanden Staat Immunogene complexen, in het bijzonder iscoms.
US5780444A (en) * 1991-12-13 1998-07-14 Trustees Of Princeton University Compositions and methods for cell transformation
US5795870A (en) * 1991-12-13 1998-08-18 Trustees Of Princeton University Compositions and methods for cell transformation
US5693769A (en) * 1991-12-13 1997-12-02 Transcell Technologies, Inc. Glycosylated steroid derivatives for transport across biological membranes and process for making and using same
US5650398A (en) * 1992-07-02 1997-07-22 Cambridge Biotech Corporation Drug delivery enhancement via modified saponins
DK1159974T3 (da) 1993-07-19 2007-11-26 Angiotech Pharm Inc Antiangiogene sammensætninger indeholdende taxol og en ikke-bionedbrydelig bærer og deres anvendelse
US5397778A (en) * 1994-02-25 1995-03-14 New England Deaconess Hospital Corporation Enteral formulations for treatment of inflammation and infection
AU1928295A (en) * 1994-02-25 1995-09-11 New England Deaconess Hospital Corporation Anti-inflammatory and infection protective effects of sesamin-based lignans
US5739118A (en) 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
AUPM873294A0 (en) * 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
AU686891B2 (en) * 1994-10-12 1998-02-12 Iscotec A.B. Saponin preparations and use thereof in iscoms
US5962428A (en) * 1995-03-30 1999-10-05 Apollon, Inc. Compositions and methods for delivery of genetic material
AU773686B2 (en) * 1996-02-21 2004-06-03 Intarcia Therapeutics, Inc. Use of cell membrane permeants in the treatment of cellular proliferative diseases
CA2247481A1 (en) * 1996-02-21 1997-08-28 Matrix Pharmaceutical, Inc. Use of cell membrane permeants in the treatment of cellular proliferative diseases
DK0952771T3 (da) * 1996-12-02 2008-05-19 Antigenics Inc Hidtil ukendte saponinpræparater og anvendelser deraf
CA2628857C (en) 1996-12-30 2011-09-13 Batelle Memorial Institute Formulation and method for treating neoplasms by inhalation
US6080725A (en) * 1997-05-20 2000-06-27 Galenica Pharmaceuticals, Inc. Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof
NZ500779A (en) * 1997-05-20 2001-06-29 Galenica Pharmaceuticals Inc Triterpene saponin analogs having adjuvant and immunostimulatory activity
US7153845B2 (en) 1998-08-25 2006-12-26 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets
US8765177B2 (en) 1997-09-12 2014-07-01 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets
US20040265377A1 (en) * 1997-10-27 2004-12-30 Harry Seager Solid dispersing vaccine composition for oral delivery
US20070059327A2 (en) * 1998-01-15 2007-03-15 Wyeth Streptococcus equi compositions and methods of use
US7070799B1 (en) * 1998-02-10 2006-07-04 Generex Pharmaceuticals, Inc. Method for administering insulin to the buccal region
AU3589899A (en) 1998-04-17 1999-11-08 Her Majesty The Queen In Right Of Canada As Represented By The Department Of Agriculture And Agri-Food Canada Process for recovery and purification of saponins and sapogenins from quinoa ((chenopodium quinoa))
US20010034330A1 (en) * 1998-08-10 2001-10-25 Charlotte Kensil Innate immunity-stimulating compositions of CpG and saponin and methods thereof
AU773204C (en) 1998-08-10 2005-05-19 Antigenics Llc Compositions of CPG and saponin adjuvants and methods thereof
US6262029B1 (en) 1998-08-14 2001-07-17 Galenica Pharmaceuticals, Inc. Chemically modified saponins and the use thereof as adjuvants
US7776343B1 (en) 1999-02-17 2010-08-17 Csl Limited Immunogenic complexes and methods relating thereto
EP1239876B1 (de) * 1999-11-19 2008-07-30 Csl Limited Hcv-impfstoff zusammensetzungen
AU5697001A (en) * 2000-03-31 2001-10-15 Purdue Research Foundation Method of treatment using ligand-immunogen conjugates
US7449557B2 (en) 2000-06-02 2008-11-11 University Of Connecticut Health Center Complexes of alpha (2) macroglobulin and antigenic molecules for immunotherapy
AU2001277961A1 (en) * 2000-08-07 2002-02-18 Antigenics, Llc Compositions comprising heat shock proteins or alpha(2)macroglobulin, antigenic molecules and saponins, and methods of use thereof
EP1377320B1 (de) 2001-04-04 2008-10-01 Nordic Vaccine Technology A/S Polynukleotide-bindende komplexe die sterolen und saponine enthalten
PL367102A1 (en) * 2001-05-02 2005-02-21 Purdue Research Foundation Treatment and diagnosis of macrophage mediated disease
US20030138434A1 (en) * 2001-08-13 2003-07-24 Campbell Robert L. Agents for enhancing the immune response
ATE451935T1 (de) * 2001-09-28 2010-01-15 Purdue Research Foundation Behandlungsverfahren mit liganden- immunogenkonjugaten
WO2003055514A1 (en) * 2001-12-21 2003-07-10 Antigenics Inc. Compositions comprising immunoreactive reagents and saponins, and methods of use thereof
JP2005538954A (ja) * 2002-05-31 2005-12-22 トーマス・ジェファーソン・ユニバーシティ 分子の経上皮輸送用組成物及び方法
US20040037809A1 (en) * 2002-06-28 2004-02-26 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of interferon beta
WO2004092329A2 (en) * 2003-04-08 2004-10-28 Galenica Pharmaceuticals, Inc. Semi-synthetic saponin analogs with carrier and immune stimulatory activities for dna and rna vaccines
EP1670507A4 (de) 2003-09-12 2007-10-17 Antigenics Inc Vakzine zur behandlung und prävention von herpes simplex-virusinfektion
US20050175623A1 (en) * 2004-02-10 2005-08-11 Zheng-Pin Wang Saponins as anticancer agent
BRPI0507680A (pt) * 2004-02-13 2007-07-17 Nod Pharmaceuticals Inc partìculas de fosfato de cálcio terapêuticas e métodos de fabricação e uso das mesmas
US7666914B2 (en) * 2004-06-03 2010-02-23 Richlin David M Topical preparation and method for transdermal delivery and localization of therapeutic agents
US20080287662A1 (en) * 2005-06-22 2008-11-20 Zeev Wiesman Balanites Aegyptiaca Saponins and Uses Thereof
WO2007092299A2 (en) * 2006-02-03 2007-08-16 Purdue Research Foundation Targeted conjugates and radiation
WO2009000277A1 (en) * 2007-06-27 2008-12-31 Coloplast A/S Treatment of urinary tract infections with a mixture of saponin and an antibiotic
JP5554713B2 (ja) * 2007-11-15 2014-07-23 エンドサイト，インク． 接合体を投与する方法
CN102946900A (zh) 2010-03-11 2013-02-27 免疫设计公司 用于大流行流感的疫苗
US8939388B1 (en) 2010-09-27 2015-01-27 ZoomEssence, Inc. Methods and apparatus for low heat spray drying
US9332776B1 (en) 2010-09-27 2016-05-10 ZoomEssence, Inc. Methods and apparatus for low heat spray drying
EP2675473A1 (de) 2011-02-15 2013-12-25 Immune Design Corp. Verfahren zur verbesserung von immunogenspezifischen immunreaktionen durch vektorisierte impfstoffe
SI2680712T1 (sl) 2011-03-04 2019-08-30 International Flavors & Fragrances Inc. Postopek izdelave s pršenjem sušenih spojin, zmožnih zadrževanja hlapnih spojin
US20130022728A1 (en) * 2011-03-04 2013-01-24 International Flavor & Fragrances Inc. Spray-Dried Compositions Capable of Retaining Volatile Compounds and Methods of Producing the Same
EP3632463A1 (de) 2011-04-08 2020-04-08 Immune Design Corp. Immunogene zusammensetzungen und verfahren zur verwendung der zusammensetzungen zur induzierung humoraler und zellulärer immunreaktionen
WO2012149307A2 (en) 2011-04-27 2012-11-01 Immune Design Corp. Synthetic long peptide (slp)-based vaccines
NZ701881A (en) 2012-05-16 2016-10-28 Immune Design Corp Vaccines for hsv-2
WO2015017280A1 (en) * 2013-07-28 2015-02-05 Qantu Therapeutics, Inc. Vaccine formulations that induce a th2 immune response
CN105960241A (zh) 2014-01-21 2016-09-21 免疫设计公司 用于治疗过敏性病症的组合物
CA2939093A1 (en) 2014-02-14 2015-08-20 Immune Design Corp. Immunotherapy of cancer through combination of local and systemic immune stimulation
AU2015289773A1 (en) 2014-07-15 2017-02-02 Immune Design Corp. Prime-boost regimens with a TLR4 agonist adjuvant and a lentiviral vector
CA2984643A1 (en) 2015-05-13 2016-11-17 Agenus Inc. Vaccines for treatment and prevention of cancer
WO2018231706A1 (en) 2017-06-11 2018-12-20 Molecular Express, Inc. Methods and compositions for substance use disorder vaccine formulations and uses thereof
CA3071115C (en) 2017-08-04 2022-06-21 ZoomEssence, Inc. Ultrahigh efficiency spray drying apparatus and process
US10155234B1 (en) 2017-08-04 2018-12-18 ZoomEssence, Inc. Ultrahigh efficiency spray drying apparatus and process
US10486173B2 (en) 2017-08-04 2019-11-26 ZoomEssence, Inc. Ultrahigh efficiency spray drying apparatus and process
US9993787B1 (en) 2017-08-04 2018-06-12 ZoomEssence, Inc. Ultrahigh efficiency spray drying apparatus and process
US9861945B1 (en) 2017-08-04 2018-01-09 ZoomEssence, Inc. Ultrahigh efficiency spray drying apparatus and process
US10569244B2 (en) 2018-04-28 2020-02-25 ZoomEssence, Inc. Low temperature spray drying of carrier-free compositions
WO2020044267A1 (en) 2018-08-29 2020-03-05 Centre Hospitalier Universitaire Vaudois Ebola vaccine compositions and methods of using same
EP4003425A2 (de) * 2019-07-25 2022-06-01 Sapreme Technologies B.V. Mit einer funktionellen einheit verbundenes bioaktives saponin
JP2023504659A (ja) 2019-12-03 2023-02-06 ニューボーゲン，インコーポレイティド 腫瘍細胞ワクチン
EP4126029A1 (de) 2020-03-23 2023-02-08 Loyola University of Chicago Coronavirus-impfstoffzusammensetzungen und verfahren zur verwendung davon
IL299356A (en) * 2020-06-24 2023-02-01 Sapreme Tech Bv hydrazone derivatives of saponin
WO2021260061A2 (en) * 2020-06-24 2021-12-30 Sapreme Technologies B.V. Saponin derivatives with improved therapeutic window
EP4236995A2 (de) 2020-11-02 2023-09-06 Neuvogen, Inc. Impfstoffe gegen tumorzellen
CN113480985A (zh) * 2021-07-07 2021-10-08 东营煜煌能源技术有限公司 一种微纳米膨胀胶束弹性颗粒驱油乳液制备方法及应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD160763A3 (de) * 1978-06-05 1984-03-07 Loeffler Friedrich Inst Verfahren zur herstellung von konzentratvakzinen
FR2456116A1 (fr) * 1979-05-11 1980-12-05 Sarget Lab Nouvelle saponine triterpenique derivee de la caulophyllogenine et ses applications therapeutiques
GB2064320B (en) * 1979-10-13 1983-10-12 Welsh Nat School Med Intra-ocular irrigation fluid
US4443432A (en) * 1981-10-05 1984-04-17 Alcon Laboratories, Inc. Ophthmalic irrigating solution
US4550022A (en) * 1981-10-05 1985-10-29 Alcon Laboratories, Inc. Tissue irrigating solution
US4548922A (en) * 1983-06-06 1985-10-22 Beth Israel Hospital Drug administration
NZ217844A (en) * 1985-10-11 1989-10-27 Sumitomo Pharma A sustained release pharmaceutical composition containing silicone elastomer and an albumin
JPS62126135A (ja) * 1985-11-25 1987-06-08 Sumitomo Pharmaceut Co Ltd 経鼻投与用ｇｒｆ製剤
US4938970A (en) * 1987-02-06 1990-07-03 Hustead Robert E Painless electrolyte solutions
US5166139A (en) * 1987-02-26 1992-11-24 Indena, S.P.A. Complexes of saponins and their aglycons with phospholipids and pharmaceutical and cosmetic compositions containing them
US5583112A (en) * 1987-05-29 1996-12-10 Cambridge Biotech Corporation Saponin-antigen conjugates and the use thereof
US5057540A (en) * 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
CA1331443C (en) * 1987-05-29 1994-08-16 Charlotte A. Kensil Saponin adjuvant
US5118676A (en) * 1988-04-08 1992-06-02 Whitby Research, Inc. Penetration enhancers for transdermal delivery of systemic agents
US5118692A (en) * 1988-04-08 1992-06-02 Whitby Research, Inc. Penetration enhances for transdermal delivery of systemic agents
US5182258A (en) * 1989-03-20 1993-01-26 Orbon Corporation Systemic delivery of polypeptides through the eye

Also Published As

Publication number Publication date
MX9303977A (es) 1994-04-29
CA2139437A1 (en) 1994-01-20
JP3684370B2 (ja) 2005-08-17
EP0658111B1 (de) 1999-10-13
AU687005B2 (en) 1998-02-19
EP0658111A1 (de) 1995-06-21
JPH07509440A (ja) 1995-10-19
EP0658111A4 (de) 1996-02-07
BR9306594A (pt) 1998-12-08
HUT73814A (en) 1996-09-30
AU4664993A (en) 1994-01-31
US5443829A (en) 1995-08-22
FI946173A (fi) 1995-02-15
HU9500001D0 (en) 1995-03-28
DE69326772T2 (de) 2000-06-29
US5273965A (en) 1993-12-28
FI946173A0 (fi) 1994-12-30
WO1994001118A1 (en) 1994-01-20

Similar Documents

Publication Publication Date Title
DE69326772T2 (de) Verfahren zur steigerung der arzneistoffabgabe mit modifizierten saponinen
DE69432167D1 (de) System zur Kontrastmittelabgabe
ATA197488A (de) Optischer sensor und verfahren zu dessen herstellung
DE69302933T2 (de) Arzneimittelabgabesystem
DE3881152D1 (de) Auslieferungssysteme zur geschmacks- und suessigkeitserhoehung und verfahren zur herstellung derselben.
DE59303882D1 (de) Verfahren zur regelung der fahrzeugstabilität
DE3888177T2 (de) Schnellauflösbare arzneimitteldosierungseinheit sowie verfahren zur herstellung.
NO933971D0 (no) Kontrollert leveringssystem med forlenget avgivelse for roeyke-opphoer
DE68905735D1 (de) Synthetisches geschmolzenes quarzglas und verfahren zu dessen herstellung.
DE68926448T2 (de) Bildsensor und verfahren zu dessen herstellung
ATA3292A (de) Vorrichtung zur selbst-injektion
IT1219457B (it) Metodo per iniettare sostanze adesive
ATA216391A (de) Reflektierende erzeugnisse und verfahren zur herstellung derselben
DE3688718T2 (de) Verfahren und System zur gleichmässigen Verschiebung.
DE69332556D1 (de) Verfahren zur Mehrfehlerkorrektur
DE69316385T2 (de) Verfahren zur reinigung von acetanhydrid
DE69306292D1 (de) Vorrichtung zur Einspritzung eines Medikaments
DE69723995D1 (de) Vorrichtung zur iontophoretischen verabreichung von medikamenten mit verfahren zur aktivierung derselben
DE69313315D1 (de) Verfahren zur Kontrastkorrektur
DE69310193T2 (de) Verfahren zur hydroxycarboxylierung der pentensäuren
DE69128314D1 (de) Vorrichtung zur transdermalen Arzneimittelabgabe
DE68906593T2 (de) Verfahren zur verhinderung des bleiziehens.
DE3873684D1 (de) Lipidemulsion und verfahren zur intravenoesen infusion.
DE69120044D1 (de) Verfahren zur Anzeigesteuerung
DE69121919D1 (de) Verfahren zur darstellung alpha-substituierter omega-hydroperfluoralkane

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: AQUILA BIOPHARMACEUTICALS, INC., FRAMINGHAM, MASS.

8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee